Mainstream-Media Explainer Wave for Medicare GLP-1 Bridge Demonstration (Launches Wednesday July 1, 2 Days Out): Washington Post, CBS News, and CNBC Publish Consumer-Facing Guides on the First Medicare Coverage of Obesity-Only GLP-1 Prescriptions at $50/Month Copay Through Humana Central Processing for Foundayo, Wegovy, and Zepbound KwikPen
Mainstream-media coverage of the Medicare GLP-1 Bridge demonstration intensified through the weekend ahead of Wednesday's July 1 launch. The Washington Post published 'Medicare is about to cover GLP-1 drugs for weight loss. Here's what to know' on June 29; CBS News ran a parallel explainer the same day; CNBC's June 28 piece flagged that a large share of eligible seniors may not yet know about the coverage expansion. The shared message across the three outlets: the program is the first time Medicare will help pay for drugs prescribed solely for obesity (rather than for diabetes, cardiovascular risk, or another approved indication), the $50/month copay applies to Foundayo (orforglipron tablets), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound KwikPen, the demonstration runs through December 31, 2027, and Humana acts as the single central processor for prior authorization and claims adjudication. CMS estimates several hundred thousand Medicare Part D beneficiaries will qualify under the three-tier BMI eligibility framework (BMI ≥35; BMI ≥30 with comorbid heart failure, uncontrolled hypertension, or chronic kidney disease; BMI ≥27 with prediabetes, prior MI, prior stroke, or peripheral artery disease). The Bridge transitions to the broader BALANCE Model launching January 2027 in Medicare Part D.